Literature DB >> 29249006

Quantified frequency-domain optical coherence tomography analysis for the thin-high signals on restenotic tissue after paclitaxel-coated balloon angioplasty.

Hideyuki Kawashima1, Nobuaki Suzuki2,3, Taiga Katayama1, Shinji Takahashi1, Ryuta Okabe1, Shintaro Takamura1, Yusuke Watanabe1, Hiroyuki Kyono1, Ken Kozuma1.   

Abstract

Thin-high signals (THS), detectable by optical coherence tomography (OCT), represent the paclitaxel coverage of in-stent restenotic tissue. This study was conducted to assess the relationship between THS and angiographic outcomes by means of quantified post-procedural frequency-domain OCT (FD-OCT) analysis. From January 2014 to July 2016, 41 patients underwent FD-OCT-guided percutaneous coronary intervention using paclitaxel-coated balloon (PCB) to prevent in-stent restenosis. Of these, we retrospectively enrolled 32 patients (38 lesions) who underwent a 6- to 9-month follow-up angiogram. THS were assessed quantitatively, as THS length and lumen perimeter length were measured using semi-automated software; %THS was calculated by the following formula; total THS area/lumen perimeter area × 100. THS were detected in all 38 lesions that had undergone PCB angioplasty. THS and %THS were significantly higher in lesions without binary restenosis (3.34 ± 2.11 vs. 11.48 ± 8.53 mm2, p = 0.001 and 1.49 ± 0.73 vs. 4.42 ± 2.71%, p = 0.001, respectively). Values for THS, which indicates the paclitaxel coverage on restenotic tissue, are associated with reducing restenosis after PCB for in-stent restenosis.

Entities:  

Keywords:  Coronary artery; Optical coherence tomography; Paclitaxel-coated balloon; Restenosis; Stent

Mesh:

Substances:

Year:  2017        PMID: 29249006     DOI: 10.1007/s00380-017-1103-3

Source DB:  PubMed          Journal:  Heart Vessels        ISSN: 0910-8327            Impact factor:   2.037


  17 in total

1.  Addition of paclitaxel to contrast media prevents restenosis after coronary stent implantation.

Authors:  Bruno Scheller; Ulrich Speck; Alexander Schmitt; Michael Böhm; Georg Nickenig
Journal:  J Am Coll Cardiol       Date:  2003-10-15       Impact factor: 24.094

2.  Incidence and distribution of thin-high signals detected by coronary optical coherence tomography in patients treated with paclitaxel-coated balloon angioplasty for in-stent restenosis.

Authors:  Hideyuki Kawashima; Nobuaki Suzuki; Hiroyuki Kyono; Miho Mitsui; Seiji Okabe; Yusuke Watanabe; Shuichi Ishikawa; Ken Kozuma
Journal:  Int J Cardiol       Date:  2015-10-08       Impact factor: 4.164

3.  Drug eluting balloon versus drug eluting stent in percutaneous coronary interventions: insights from a meta-analysis of 1462 patients.

Authors:  Alessandro Lupi; Andrea Rognoni; Gioel Gabrio Secco; Italo Porto; Federico Nardi; Maurizio Lazzero; Lidia Rossi; Rosario Parisi; Rossella Fattori; Giulia Genoni; Roberta Rosso; Pieter R Stella; Imad Sheiban; Leonardo Bolognese; Francesco Liistro; Angelo Sante Bongo; Pierfrancesco Agostoni
Journal:  Int J Cardiol       Date:  2013-07-26       Impact factor: 4.164

4.  Incidence, predictors and outcomes of immediate decrease in thrombolysis in myocardial infarction flow immediately after paclitaxel-coated balloon angioplasty.

Authors:  Hideyuki Kawashima; Nobuaki Suzuki; Hiroyuki Kyono; Hiroaki Nakaya; Yugo Nara; Yusuke Watanabe; Shuichi Ishikawa; Ken Kozuma
Journal:  Int J Cardiol       Date:  2015-05-09       Impact factor: 4.164

5.  Coronary angioscopy and optical coherence tomography for confirmation of drug-coated neointimal plaque after paclitaxel-coated balloon angioplasty for in-stent restenosis.

Authors:  Kihei Yoneyama; Kohei Koyama; Yasuhiro Tanabe; Takanobu Mitarai; Ryo Kamijima; Shingo Kuwata; Hiroshi Yamazaki; Emi Nakano; Ken Kongoji; Tomoo Harada; Yoshihiro J Akashi
Journal:  Int J Cardiol       Date:  2014-08-05       Impact factor: 4.164

6.  Restenosis after successful percutaneous transluminal coronary angioplasty: serial angiographic follow-up of 229 patients.

Authors:  M Nobuyoshi; T Kimura; H Nosaka; S Mioka; K Ueno; H Yokoi; N Hamasaki; H Horiuchi; H Ohishi
Journal:  J Am Coll Cardiol       Date:  1988-09       Impact factor: 24.094

7.  Optical coherence tomography compared with intravascular ultrasound and with angiography to guide coronary stent implantation (ILUMIEN III: OPTIMIZE PCI): a randomised controlled trial.

Authors:  Ziad A Ali; Akiko Maehara; Philippe Généreux; Richard A Shlofmitz; Franco Fabbiocchi; Tamim M Nazif; Giulio Guagliumi; Perwaiz M Meraj; Fernando Alfonso; Habib Samady; Takashi Akasaka; Eric B Carlson; Massoud A Leesar; Mitsuaki Matsumura; Melek Ozgu Ozan; Gary S Mintz; Ori Ben-Yehuda; Gregg W Stone
Journal:  Lancet       Date:  2016-10-30       Impact factor: 79.321

8.  Association between tissue characteristics assessed with optical coherence tomography and mid-term results after percutaneous coronary intervention for in-stent restenosis lesions: a comparison between balloon angioplasty, paclitaxel-coated balloon dilatation, and drug-eluting stent implantation.

Authors:  Takeshi Tada; Kazushige Kadota; Shingo Hosogi; Koshi Miyake; Masanobu Ohya; Hideo Amano; Yu Izawa; Takenori Kanazawa; Shunsuke Kubo; Tahei Ichinohe; Yusuke Hyoudou; Yuki Hayakawa; Mahmoud Mohamed Hassan Sabbah; Suguru Otsuru; Daiji Hasegawa; Seiji Habara; Hiroyuki Tanaka; Yasushi Fuku; Harumi Katoh; Tsuyoshi Goto; Kazuaki Mitsudo
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2015-03-09       Impact factor: 6.875

9.  Mechanisms of tissue uptake and retention in zotarolimus-coated balloon therapy.

Authors:  Vijaya B Kolachalama; Stephen D Pacetti; Joseph W Franses; John J Stankus; Hugh Q Zhao; Tarek Shazly; Alexander Nikanorov; Lewis B Schwartz; Abraham R Tzafriri; Elazer R Edelman
Journal:  Circulation       Date:  2013-04-12       Impact factor: 29.690

10.  Optical coherence tomography patterns of stent restenosis.

Authors:  Nieves Gonzalo; Patrick W Serruys; Takayuki Okamura; Heleen M van Beusekom; Hector M Garcia-Garcia; Gijs van Soest; Wim van der Giessen; Evelyn Regar
Journal:  Am Heart J       Date:  2009-08       Impact factor: 4.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.